Cellular localization and functional characterization of the equilibrative nucleoside transporters of antitumor nucleosides

Cancer Science

Volumn 98, Issue 10, 2007, Pages 1633-1637

  Yoshio, Endo ^a   Obata, Tohru ^a,b   Murata, Daigo ^a   Ito, Mariho ^a   Sakamoto, Kazuki ^a,c   Fukushima, Masakazu ^c   Yamasaki, Yasundo ^c   Yamada, Yuji ^c   Natsume, Nagato ^b   Sasaki, Takuma ^a,b  

^a KANAZAWA UNIVERSITY   (Japan)

^b AICHI GAKUIN UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3' ETHYNYLCYTIDINE; CYTARABINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 2; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 3; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 4; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL MEMBRANE; CELL ORGANELLE; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FIBROSARCOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; STOMACH CARCINOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL TRANSPORT; CELL MEMBRANE; CELL PROLIFERATION; CYTARABINE; CYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORT PROTEINS; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; EQUILIBRATIVE-NUCLEOSIDE TRANSPORTER 2; FIBROSARCOMA; GREEN FLUORESCENT PROTEINS; HUMANS; NUCLEOSIDE TRANSPORT PROTEINS; RNA, MESSENGER; STOMACH NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 34548149998     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2007.00581.x     Document Type: Article

References (34)

1. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V. Gemcitabine: Metabolism, mechanisms of action, and self-potentiation. Semin Oncol 1995; 22: 3-10.
2. Bhalla K, Nayak R, Grant S. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-d-arabinofuranosylcytosine. Cancer Res 1984; 44: 5029-37.
3. Kees UR, Ford J, Dawson VM, Piall E, Aherne GW. Development of resistance to 1-β-d-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: Analysis of resistance mechanism in established cell lines. Cancer Res 1989; 49: 3015-19.
4. Tsuruo T, Naganuma K, Iida H et al. Establishment of human KB cells resistant to 1-β-d-arabinofuranosylcytosine, and mechanisms of cellular resistance in isolated clones. Gann 1984; 75: 690-8.
5. Owens JK, Shewach DS, Ullman B, Mitchell BS. Resistance to 1-β-d-arabinofuranosylcytosine in human T-lymphoblasts mediated by mutations within the deoxycytidine kinase gene. Cancer Res 1992; 52: 2389-93.
6. Obata T, Endo Y, Tanaka M, Matsuda A, Sasaki T. Development and biochemical characterization of a 2′-C-cyano-2′-deoxy-1- β-d-arabino-pentofuranosylcytosine (CNDAC)-resistant variant of the human fibrosarcoma cell line HT-1080. Cancer Lett 1998; 123: 53-61.
7. Obata T, Endo Y, Tanaka M, Uchida H, Matsuda A, Sasaki T. Deletion mutants of human deoxycytidine kinase mRNA in cells resistant to antitumor cytosine nucleosides. Jpn J Cancer Res 2001; 92: 793-8.
8. Hattori H, Tanaka M, Fukushima M, Sasaki T, Matsuda A. Nucleosides and nucleotides. 158. 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) uracil, and their nucleobase analogues as new potential multifunctional antitumor nucleosides with a broad spectrum of activity. J Medical Chem 1996; 39: 5005-11.
9. Kanda H, Takatori S, Matsuda A et al. Cytotoxic mechanisms of new antitumor nucleoside analogues, 3′-ethynylcytidine (ECyd) and 3′-ethynyluridine (EUrd). Nucleic Acids Symp Ser 1997; (37): 137-8.
10. Tabata S, Tanaka M, Endo Y, Obata T, Matsuda A, Sasaki T. Anti-tumor mechanisms of 3′-ethynyluridine and 3′-ethynylcytidine as RNA synthesis inhibitors: Development and characterization of 3′-ethynyluridine-resistant cells. Cancer Lett 1997; 116: 225-31.
11. Matsuda A, Fukushima M, Wataya Y, Sasaki T. A new antitumor nucleoside, 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine (ECyd), is a potent inhibitor of RNA synthesis. Nucleosides Nucleotides 1999; 18: 811-14.
12. Azuma A, Matsuda A, Sasaki T, Fukushima M. 1-(3-C-ethynyl-β-d-ribo-pentofuranosyl) cytosine (ECyd, TAS-106) 1: antitumor effect and mechanism of action. Nucleosides Nucleotides Nucl Acids 2001; 20: 609-19.
13. Shimamoto Y, Fujioka A, Kazuno H et al. Antitumor activity and pharmacokinetics of TAS-106, 1-(3-C-ethynyl-β- d -ribo-pentofuranosyl) cytosine. Jpn J Cancer Res 2001; 92: 343-51.
14. Koizumi K, Shimamoto Y, Azuma A et al. Cloning and expression of uridine/ cytidine kinase cDNA from human fibrosarcoma cells. Int J Mol Med 2001; 8: 273-8.
15. Murata D, Endo Y, Obata T et al. A crucial role of uridine/cytidine kinase 2 in antitumor activity of 3′-ethynyl nucleosides. Drug Metab Dispos 2004; 32: 1178-82.
16. Hyde RJ, Cass CE, Young JD, Baldwin SA. The ENT family of eukaryote nucleoside and nucleobase transporters: Recent advances in the investigation of structure/function relationships and the identification of novel isoforms. Mol Membr Biol 2001; 18: 53-63.
17. Galmarini CM, Thomas X, Calvo F et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 2002; 26: 621-9.
18. Obata T, Endo Y, Murata D, Sakamoto K, Sasaki T. The molecular targets of antitumor 2′-deoxycytidine analogues. Curr Drug Targets 2003; 4: 305-13.
19. Achiwa H, Oguri T, Sato S, Maeda H, Niimi T, Ueda R. Determinants of sensitivity and resistance to gemcitabine: The roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 2004; 95: 753-7.
20. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735-43.
21. Kong W, Engel K, Wang J. Mammalian nucleoside transporters. Curr Drug Metab 2004; 5: 63-84.
22. Pastor-Anglada M, Cano-Soldado P, Molina-Arcas M et al. Cell entry and export of nucleoside analogues. Virus Res 2005; 107: 151-64.
23. Baldwin SA, Mackey JR, Cass CE, Young JD. Nucleoside transporters: molecular biology and implications for therapeutic development. Mol Med Today 1999; 5: 216-24.
24. Cass CE, Young JD, Baldwin SA et al. Nucleoside transporters of mammalian cells. Pharm Biotechnol 1999; 12: 313-52.
25. Gray JH, Owen RP, Giacomini KM. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 2004; 447: 728-34.
26. Griffith DA, Jarvis SM. Nucleoside and nucleobase transport systems of mammalian cells. Biochim Biophys Acta 1996; 1286: 153-81.
27. Mangravite LM, Badagnani I, Giacomini KM. Nucleoside transporters in the disposition and targeting of nucleoside analogs in the kidney. Eur J Pharmacol 2003; 479: 269-81.
28. Lai Y, Bakken AH, Unadkat JD. Simultaneous expression of hCNT1-CFP and hENT1-YFP in Madin-Darby canine kidney cells: Localization and vectorial transport studies. J Biol Chem 2002; 277: 37 711-17.
29. Baldwin SA, Yao SY, Hyde RJ et al. Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J Biol Chem 2005; 280: 15 880-7.
30. Barnes K, Dobrzynski H, Foppolo S et al. Distribution and functional characterization of equilibrative nucleoside transporter-4, a novel cardiac adenosine transporter activated at acidic pH. Circ Res 2006; 99: 510-19.
31. Engel K, Zhou M, Wang J. Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem 2004; 279: 50 042-9.
32. Matsuda A, Nakajima Y, Azuma A, Tanaka M, Sasaki T. Nucleosides and nucleotides. 100. 2′-C-cyano-2′-deoxy-1 -β-d-arabinofuranosyl-cytosine (CNDAC): Design of a potential mechanism-based DNA-strand-breaking antineoplastic nucleoside. J Med Chem 1991; 34: 2917-19.
33. Carmichael J, DeGraff WG, Gazdar AF, Minna JD, Mitchell JB. Evaluation of a tetrazolium-based semiautomated colorimetric assay: Assessment of chemosensitivity testing. Cancer Res 1987; 47: 936-42.
34. Tanaka M, Matsuda A, Terao T, Sasaki T. Antitumor activity of a novel nucleoside, 2′-C-cyano-2′-deoxy-1-β- D-arabinofuranosylcytosine (CNDAC) against murine and human tumors. Cancer Lett 1992; 64: 67-74.